English

GenSight Biologics

ESEF

Report (type unavailable) · filed 2025-04-15

Annual consolidated revenue for 2024: about EUR 1.5M, using the latest reported figures. The previous period, 2023, was about EUR 1.267M.

Inspect reported changes Compare with another company Historical disclosures Segments

Watchlist

Latest fiscal year

Revenue

1.5 million EUR

2024 · EUR

Exact inputs and evidence

Revenue: 1500000 EUR Source

Operating margin

-1,054.2%

2024 · %

Exact inputs and evidence

Operating Income: -15813000 EUR Source
Revenue: 1500000 EUR Source

Operating cash flow

-12.9 million EUR

2024 · EUR

Exact inputs and evidence

Operating Cash Flow: -12937000 EUR Source

Free cash flow

-12.9 million EUR

2024 · EUR

Exact inputs and evidence

Operating Cash Flow: -12937000 EUR Source
Capital Expenditure: 1000 EUR Source

Cash and cash equivalents: 2.46 million EUR 2024-12-31 Source
Exact value

2464000 EUR
Long-term debt including current maturities: Not available
Shares outstanding: Not available

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2025-04-15.

Financial data available through: 2024-12-31.

Coverage by financial measure

Revenue: 5 of 11 periods available· newest 2024-12-31
Operating income: 5 of 11 periods available· newest 2024-12-31
net income: No compatible figures in this window
Operating cash flow: 5 of 11 periods available· newest 2024-12-31
Capital expenditure: 5 of 11 periods available· newest 2024-12-31
Total assets: 5 of 11 periods available· newest 2024-12-31
liabilities: No compatible figures in this window
Current assets: 5 of 11 periods available· newest 2024-12-31
Current liabilities: 5 of 11 periods available· newest 2024-12-31
Cash and cash equivalents: 5 of 11 periods available· newest 2024-12-31
long term debt: No compatible figures in this window
shares outstanding: No compatible figures in this window

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+18.4%

Prior period

EUR 1.27 million

2023-01-01 – 2023-12-31
Current period

EUR 1.5 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

1500000 − 1267000 = 233000 EUR

1267000 EUR · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
1500000 EUR · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · GenSight Biologics · 2024-12-31 GenSight Biologics (esef:549300NK4AB8OUEX1F54) Year-over-year change in Revenue: 233000 EUR Concept: fundies:Revenue Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-10T08:41:54Z Snapshot: 09f981f11f49334443a5e46570bc78a4f6976a0e0d97fcf09f8e37a91cb4734d Dimensions: Consolidated View: https://fundies.io/companies/esef/549300NK4AB8OUEX1F54?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 1500000 EUR (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/549300NK4AB8OUEX1F54/2024-12-31/ESEF/FR/0/549300NK4AB8OUEX1F54-2024-12-31-0-EN.zip#30116405 Filing: 549300NK4AB8OUEX1F54-2024-12-31-ESEF-FR-0 Input fundies:Revenue: 1267000 EUR (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/549300NK4AB8OUEX1F54/2024-12-31/ESEF/FR/0/549300NK4AB8OUEX1F54-2024-12-31-0-EN.zip#30117033 Filing: 549300NK4AB8OUEX1F54-2024-12-31-ESEF-FR-0
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+EUR 11.73 million

Prior period

−EUR 24.66 million

2023-01-01 – 2023-12-31
Current period

−EUR 12.94 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-12937000 − -24663000 = 11726000 EUR

-24663000 EUR · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-12937000 EUR · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · GenSight Biologics · 2024-12-31 GenSight Biologics (esef:549300NK4AB8OUEX1F54) Year-over-year change in Operating cash flow: 11726000 EUR Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-10T08:41:54Z Snapshot: 09f981f11f49334443a5e46570bc78a4f6976a0e0d97fcf09f8e37a91cb4734d Dimensions: Consolidated View: https://fundies.io/companies/esef/549300NK4AB8OUEX1F54?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -12937000 EUR (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/549300NK4AB8OUEX1F54/2024-12-31/ESEF/FR/0/549300NK4AB8OUEX1F54-2024-12-31-0-EN.zip#30194781 Filing: 549300NK4AB8OUEX1F54-2024-12-31-ESEF-FR-0 Input fundies:OperatingCashFlow: -24663000 EUR (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/549300NK4AB8OUEX1F54/2024-12-31/ESEF/FR/0/549300NK4AB8OUEX1F54-2024-12-31-0-EN.zip#30195454 Filing: 549300NK4AB8OUEX1F54-2024-12-31-ESEF-FR-0
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-90%

Prior period

EUR 10,000

2023-01-01 – 2023-12-31
Current period

EUR 1,000

2024-01-01 – 2024-12-31

Exact inputs and evidence

1000 − 10000 = -9000 EUR

10000 EUR · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
1000 EUR · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · GenSight Biologics · 2024-12-31 GenSight Biologics (esef:549300NK4AB8OUEX1F54) Year-over-year change in Capital expenditure: -9000 EUR Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-10T08:41:54Z Snapshot: 09f981f11f49334443a5e46570bc78a4f6976a0e0d97fcf09f8e37a91cb4734d Dimensions: Consolidated View: https://fundies.io/companies/esef/549300NK4AB8OUEX1F54?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 1000 EUR (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/549300NK4AB8OUEX1F54/2024-12-31/ESEF/FR/0/549300NK4AB8OUEX1F54-2024-12-31-0-EN.zip#30198945 Filing: 549300NK4AB8OUEX1F54-2024-12-31-ESEF-FR-0 Input fundies:CapitalExpenditure: 10000 EUR (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/549300NK4AB8OUEX1F54/2024-12-31/ESEF/FR/0/549300NK4AB8OUEX1F54-2024-12-31-0-EN.zip#30199630 Filing: 549300NK4AB8OUEX1F54-2024-12-31-ESEF-FR-0
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Net income.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2024 2024-01-01 – 2024-12-31

Revenue EUR 1.5 million 100% of revenue
Operating costs Derived EUR 17.31 million 1,154% of revenue
Operating income −EUR 15.81 million −1,054% of revenue
Tax, interest and other Derived Unavailable An input is unavailable.
Net income Unavailable An input is unavailable.

Cash

Operating cash flow −EUR 12.94 million −862% of revenue
Capital expenditure EUR 1,000 0.1% of revenue
Free cash flow Derived −EUR 12.94 million −863% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2020 Not shown: operating income or net income is not reported.
2021 Not shown: operating income or net income is not reported.
2022 Not shown: operating income or net income is not reported.
2023 Not shown: operating income or net income is not reported.
2024 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2020 2020-01-01 – 2020-12-31	4394000	29328000 Derived	-24934000	Unavailable	Unavailable	-15050000 Derived	Source 2020-01-01 – 2020-12-31: 4394000 EUR Inspect Revenue Open source 2020-01-01 – 2020-12-31: -24934000 EUR Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -15044000 EUR Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 6000 EUR Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	5276000	33402000 Derived	-28126000	Unavailable	Unavailable	-17171000 Derived	Source 2021-01-01 – 2021-12-31: 5276000 EUR Inspect Revenue Open source 2021-01-01 – 2021-12-31: -28126000 EUR Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -17139000 EUR Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 32000 EUR Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	2582000	30417000 Derived	-27835000	Unavailable	Unavailable	-34005000 Derived	Source 2022-01-01 – 2022-12-31: 2582000 EUR Inspect Revenue Open source 2022-01-01 – 2022-12-31: -27835000 EUR Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -33753000 EUR Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 252000 EUR Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	1267000	30963000 Derived	-29696000	Unavailable	Unavailable	-24673000 Derived	Source 2023-01-01 – 2023-12-31: 1267000 EUR Inspect Revenue Open source 2023-01-01 – 2023-12-31: -29696000 EUR Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -24663000 EUR Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 10000 EUR Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	1500000	17313000 Derived	-15813000	Unavailable	Unavailable	-12938000 Derived	Source 2024-01-01 – 2024-12-31: 1500000 EUR Inspect Revenue Open source 2024-01-01 – 2024-12-31: -15813000 EUR Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -12937000 EUR Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 1000 EUR Inspect Capital Expenditure Open source

Amounts are exact, in EUR.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

EUR 1.5M 2024

Values and sources

Revenue values and source evidence
Period	Series	Value(EUR)	Source evidence
20202020-12-31	Revenue	4394000	Revenue: 4394000 Open source
20212021-12-31	Revenue	5276000	Revenue: 5276000 Open source
20222022-12-31	Revenue	2582000	Revenue: 2582000 Open source
20232023-12-31	Revenue	1267000	Revenue: 1267000 Open source
20242024-12-31	Revenue	1500000	Revenue: 1500000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

18.4% 2024

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Year over year	No prior comparable period	Revenue: 4394000 Open source
20212021-12-31	Year over year	20.1%	Revenue: 5276000 Open source Revenue: 4394000 Open source
20222022-12-31	Year over year	-51.1%	Revenue: 2582000 Open source Revenue: 5276000 Open source
20232023-12-31	Year over year	-50.9%	Revenue: 1267000 Open source Revenue: 2582000 Open source
20242024-12-31	Year over year	18.4%	Revenue: 1500000 Open source Revenue: 1267000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -1,054.2% 2024

Free cash flow margin -862.5% 2024

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Operating margin	-567.5%	Operating Income: -24934000 Open source Revenue: 4394000 Open source
20212021-12-31	Operating margin	-533.1%	Operating Income: -28126000 Open source Revenue: 5276000 Open source
20222022-12-31	Operating margin	-1,078%	Operating Income: -27835000 Open source Revenue: 2582000 Open source
20232023-12-31	Operating margin	-2,343.8%	Operating Income: -29696000 Open source Revenue: 1267000 Open source
20242024-12-31	Operating margin	-1,054.2%	Operating Income: -15813000 Open source Revenue: 1500000 Open source
2020-12-31	Net margin	Not reported	Revenue: 4394000 Open source
2021-12-31	Net margin	Not reported	Revenue: 5276000 Open source
2022-12-31	Net margin	Not reported	Revenue: 2582000 Open source
2023-12-31	Net margin	Not reported	Revenue: 1267000 Open source
2024-12-31	Net margin	Not reported	Revenue: 1500000 Open source
20202020-12-31	Free cash flow margin	-342.5%	Revenue: 4394000 Open source Operating Cash Flow: -15044000 Open source Capital Expenditure: 6000 Open source
20212021-12-31	Free cash flow margin	-325.5%	Revenue: 5276000 Open source Operating Cash Flow: -17139000 Open source Capital Expenditure: 32000 Open source
20222022-12-31	Free cash flow margin	-1,317%	Revenue: 2582000 Open source Operating Cash Flow: -33753000 Open source Capital Expenditure: 252000 Open source
20232023-12-31	Free cash flow margin	-1,947.4%	Revenue: 1267000 Open source Operating Cash Flow: -24663000 Open source Capital Expenditure: 10000 Open source
20242024-12-31	Free cash flow margin	-862.5%	Revenue: 1500000 Open source Operating Cash Flow: -12937000 Open source Capital Expenditure: 1000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

EUR -12.9M 2024

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(EUR)	Source evidence
20202020-12-31	Operating cash flow	-15044000	Operating Cash Flow: -15044000 Open source
20212021-12-31	Operating cash flow	-17139000	Operating Cash Flow: -17139000 Open source
20222022-12-31	Operating cash flow	-33753000	Operating Cash Flow: -33753000 Open source
20232023-12-31	Operating cash flow	-24663000	Operating Cash Flow: -24663000 Open source
20242024-12-31	Operating cash flow	-12937000	Operating Cash Flow: -12937000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

EUR -12.9M 2024

Values and sources

Free cash flow values and source evidence
Period	Series	Value(EUR)	Source evidence
20202020-12-31	Free cash flow	-15050000	Operating Cash Flow: -15044000 Open source Capital Expenditure: 6000 Open source
20212021-12-31	Free cash flow	-17171000	Operating Cash Flow: -17139000 Open source Capital Expenditure: 32000 Open source
20222022-12-31	Free cash flow	-34005000	Operating Cash Flow: -33753000 Open source Capital Expenditure: 252000 Open source
20232023-12-31	Free cash flow	-24673000	Operating Cash Flow: -24663000 Open source Capital Expenditure: 10000 Open source
20242024-12-31	Free cash flow	-12938000	Operating Cash Flow: -12937000 Open source Capital Expenditure: 1000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2020-12-31	Liabilities / assets	Not reported	Total Assets: 47361000 Open source
2021-12-31	Liabilities / assets	Not reported	Total Assets: 56648000 Open source
2022-12-31	Liabilities / assets	Not reported	Total Assets: 25941000 Open source
2023-12-31	Liabilities / assets	Not reported	Total Assets: 9132000 Open source
2024-12-31	Liabilities / assets	Not reported	Total Assets: 10756000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0.24× 2024

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Current assets / current liabilities	2.56×	Current Assets: 43759000 Open source Current Liabilities: 17123000 Open source
20212021-12-31	Current assets / current liabilities	2.4×	Current Assets: 53363000 Open source Current Liabilities: 22242000 Open source
20222022-12-31	Current assets / current liabilities	1.57×	Current Assets: 22947000 Open source Current Liabilities: 14642000 Open source
20232023-12-31	Current assets / current liabilities	0.26×	Current Assets: 6529000 Open source Current Liabilities: 25290000 Open source
20242024-12-31	Current assets / current liabilities	0.24×	Current Assets: 5343000 Open source Current Liabilities: 22618000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2020 2020-01-01 – 2020-12-31	Unavailable Not reported for this period.	−EUR 15.04 million Exact value Exact value: -15044000 EUR 2020-01-01 – 2020-12-31: -15044000 EUR Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · GenSight Biologics · 2020-12-31 GenSight Biologics (esef:549300NK4AB8OUEX1F54) Operating Cash Flow: -15044000 EUR Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-10T08:41:54Z Snapshot: 09f981f11f49334443a5e46570bc78a4f6976a0e0d97fcf09f8e37a91cb4734d Dimensions: Consolidated View: https://fundies.io/companies/esef/549300NK4AB8OUEX1F54/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=EUR&dimensions= Input fundies:OperatingCashFlow: -15044000 EUR (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/549300NK4AB8OUEX1F54/2021-12-31/ESEF/FR/0/gensight-2021-12-31-en.zip#81230091 Filing: 549300NK4AB8OUEX1F54-2021-12-31-ESEF-FR-0 The citation records this snapshot. The page link may show a newer release later.	EUR 6,000 Exact value Exact value: 6000 EUR 2020-01-01 – 2020-12-31: 6000 EUR Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · GenSight Biologics · 2020-12-31 GenSight Biologics (esef:549300NK4AB8OUEX1F54) Capital Expenditure: 6000 EUR Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-10T08:41:54Z Snapshot: 09f981f11f49334443a5e46570bc78a4f6976a0e0d97fcf09f8e37a91cb4734d Dimensions: Consolidated View: https://fundies.io/companies/esef/549300NK4AB8OUEX1F54/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=EUR&dimensions= Input fundies:CapitalExpenditure: 6000 EUR (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/549300NK4AB8OUEX1F54/2021-12-31/ESEF/FR/0/gensight-2021-12-31-en.zip#81234131 Filing: 549300NK4AB8OUEX1F54-2021-12-31-ESEF-FR-0 The citation records this snapshot. The page link may show a newer release later.	−EUR 15.05 million Calculation and evidence -15044000 − 6000 EUR Exact free cash flow: -15050000 EUR 2020-01-01 – 2020-12-31: -15044000 EUR · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 6000 EUR · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · GenSight Biologics · 2020-12-31 GenSight Biologics (esef:549300NK4AB8OUEX1F54) Free cash flow: -15050000 EUR Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-10T08:41:54Z Snapshot: 09f981f11f49334443a5e46570bc78a4f6976a0e0d97fcf09f8e37a91cb4734d Dimensions: Consolidated View: https://fundies.io/companies/esef/549300NK4AB8OUEX1F54?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -15044000 EUR (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/549300NK4AB8OUEX1F54/2021-12-31/ESEF/FR/0/gensight-2021-12-31-en.zip#81230091 Filing: 549300NK4AB8OUEX1F54-2021-12-31-ESEF-FR-0 Input fundies:CapitalExpenditure: 6000 EUR (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/549300NK4AB8OUEX1F54/2021-12-31/ESEF/FR/0/gensight-2021-12-31-en.zip#81234131 Filing: 549300NK4AB8OUEX1F54-2021-12-31-ESEF-FR-0 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	Unavailable Not reported for this period.	−EUR 17.14 million Exact value Exact value: -17139000 EUR 2021-01-01 – 2021-12-31: -17139000 EUR Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · GenSight Biologics · 2021-12-31 GenSight Biologics (esef:549300NK4AB8OUEX1F54) Operating Cash Flow: -17139000 EUR Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-10T08:41:54Z Snapshot: 09f981f11f49334443a5e46570bc78a4f6976a0e0d97fcf09f8e37a91cb4734d Dimensions: Consolidated View: https://fundies.io/companies/esef/549300NK4AB8OUEX1F54/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=EUR&dimensions= Input fundies:OperatingCashFlow: -17139000 EUR (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/549300NK4AB8OUEX1F54/2022-12-31/ESEF/FR/0/549300NK4AB8OUEX1F54-2022-12-31-en.zip#31532782 Filing: 549300NK4AB8OUEX1F54-2022-12-31-ESEF-FR-0 The citation records this snapshot. The page link may show a newer release later.	EUR 32,000 Exact value Exact value: 32000 EUR 2021-01-01 – 2021-12-31: 32000 EUR Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · GenSight Biologics · 2021-12-31 GenSight Biologics (esef:549300NK4AB8OUEX1F54) Capital Expenditure: 32000 EUR Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-10T08:41:54Z Snapshot: 09f981f11f49334443a5e46570bc78a4f6976a0e0d97fcf09f8e37a91cb4734d Dimensions: Consolidated View: https://fundies.io/companies/esef/549300NK4AB8OUEX1F54/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=EUR&dimensions= Input fundies:CapitalExpenditure: 32000 EUR (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/549300NK4AB8OUEX1F54/2022-12-31/ESEF/FR/0/549300NK4AB8OUEX1F54-2022-12-31-en.zip#31536970 Filing: 549300NK4AB8OUEX1F54-2022-12-31-ESEF-FR-0 The citation records this snapshot. The page link may show a newer release later.	−EUR 17.17 million Calculation and evidence -17139000 − 32000 EUR Exact free cash flow: -17171000 EUR 2021-01-01 – 2021-12-31: -17139000 EUR · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 32000 EUR · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · GenSight Biologics · 2021-12-31 GenSight Biologics (esef:549300NK4AB8OUEX1F54) Free cash flow: -17171000 EUR Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-10T08:41:54Z Snapshot: 09f981f11f49334443a5e46570bc78a4f6976a0e0d97fcf09f8e37a91cb4734d Dimensions: Consolidated View: https://fundies.io/companies/esef/549300NK4AB8OUEX1F54?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -17139000 EUR (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/549300NK4AB8OUEX1F54/2022-12-31/ESEF/FR/0/549300NK4AB8OUEX1F54-2022-12-31-en.zip#31532782 Filing: 549300NK4AB8OUEX1F54-2022-12-31-ESEF-FR-0 Input fundies:CapitalExpenditure: 32000 EUR (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/549300NK4AB8OUEX1F54/2022-12-31/ESEF/FR/0/549300NK4AB8OUEX1F54-2022-12-31-en.zip#31536970 Filing: 549300NK4AB8OUEX1F54-2022-12-31-ESEF-FR-0 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	Unavailable Not reported for this period.	−EUR 33.75 million Exact value Exact value: -33753000 EUR 2022-01-01 – 2022-12-31: -33753000 EUR Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · GenSight Biologics · 2022-12-31 GenSight Biologics (esef:549300NK4AB8OUEX1F54) Operating Cash Flow: -33753000 EUR Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-10T08:41:54Z Snapshot: 09f981f11f49334443a5e46570bc78a4f6976a0e0d97fcf09f8e37a91cb4734d Dimensions: Consolidated View: https://fundies.io/companies/esef/549300NK4AB8OUEX1F54/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=EUR&dimensions= Input fundies:OperatingCashFlow: -33753000 EUR (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/549300NK4AB8OUEX1F54/2023-12-31/ESEF/FR/0/549300NK4AB8OUEX1F54-2023-12-31AR.zip#26296010 Filing: 549300NK4AB8OUEX1F54-2023-12-31-ESEF-FR-0 The citation records this snapshot. The page link may show a newer release later.	EUR 252,000 Exact value Exact value: 252000 EUR 2022-01-01 – 2022-12-31: 252000 EUR Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · GenSight Biologics · 2022-12-31 GenSight Biologics (esef:549300NK4AB8OUEX1F54) Capital Expenditure: 252000 EUR Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-10T08:41:54Z Snapshot: 09f981f11f49334443a5e46570bc78a4f6976a0e0d97fcf09f8e37a91cb4734d Dimensions: Consolidated View: https://fundies.io/companies/esef/549300NK4AB8OUEX1F54/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=EUR&dimensions= Input fundies:CapitalExpenditure: 252000 EUR (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/549300NK4AB8OUEX1F54/2023-12-31/ESEF/FR/0/549300NK4AB8OUEX1F54-2023-12-31AR.zip#26300187 Filing: 549300NK4AB8OUEX1F54-2023-12-31-ESEF-FR-0 The citation records this snapshot. The page link may show a newer release later.	−EUR 34.01 million Calculation and evidence -33753000 − 252000 EUR Exact free cash flow: -34005000 EUR 2022-01-01 – 2022-12-31: -33753000 EUR · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 252000 EUR · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · GenSight Biologics · 2022-12-31 GenSight Biologics (esef:549300NK4AB8OUEX1F54) Free cash flow: -34005000 EUR Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-10T08:41:54Z Snapshot: 09f981f11f49334443a5e46570bc78a4f6976a0e0d97fcf09f8e37a91cb4734d Dimensions: Consolidated View: https://fundies.io/companies/esef/549300NK4AB8OUEX1F54?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -33753000 EUR (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/549300NK4AB8OUEX1F54/2023-12-31/ESEF/FR/0/549300NK4AB8OUEX1F54-2023-12-31AR.zip#26296010 Filing: 549300NK4AB8OUEX1F54-2023-12-31-ESEF-FR-0 Input fundies:CapitalExpenditure: 252000 EUR (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/549300NK4AB8OUEX1F54/2023-12-31/ESEF/FR/0/549300NK4AB8OUEX1F54-2023-12-31AR.zip#26300187 Filing: 549300NK4AB8OUEX1F54-2023-12-31-ESEF-FR-0 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	Unavailable Not reported for this period.	−EUR 24.66 million Exact value Exact value: -24663000 EUR 2023-01-01 – 2023-12-31: -24663000 EUR Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · GenSight Biologics · 2023-12-31 GenSight Biologics (esef:549300NK4AB8OUEX1F54) Operating Cash Flow: -24663000 EUR Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-10T08:41:54Z Snapshot: 09f981f11f49334443a5e46570bc78a4f6976a0e0d97fcf09f8e37a91cb4734d Dimensions: Consolidated View: https://fundies.io/companies/esef/549300NK4AB8OUEX1F54/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=EUR&dimensions= Input fundies:OperatingCashFlow: -24663000 EUR (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/549300NK4AB8OUEX1F54/2024-12-31/ESEF/FR/0/549300NK4AB8OUEX1F54-2024-12-31-0-EN.zip#30195454 Filing: 549300NK4AB8OUEX1F54-2024-12-31-ESEF-FR-0 The citation records this snapshot. The page link may show a newer release later.	EUR 10,000 Exact value Exact value: 10000 EUR 2023-01-01 – 2023-12-31: 10000 EUR Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · GenSight Biologics · 2023-12-31 GenSight Biologics (esef:549300NK4AB8OUEX1F54) Capital Expenditure: 10000 EUR Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-10T08:41:54Z Snapshot: 09f981f11f49334443a5e46570bc78a4f6976a0e0d97fcf09f8e37a91cb4734d Dimensions: Consolidated View: https://fundies.io/companies/esef/549300NK4AB8OUEX1F54/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=EUR&dimensions= Input fundies:CapitalExpenditure: 10000 EUR (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/549300NK4AB8OUEX1F54/2024-12-31/ESEF/FR/0/549300NK4AB8OUEX1F54-2024-12-31-0-EN.zip#30199630 Filing: 549300NK4AB8OUEX1F54-2024-12-31-ESEF-FR-0 The citation records this snapshot. The page link may show a newer release later.	−EUR 24.67 million Calculation and evidence -24663000 − 10000 EUR Exact free cash flow: -24673000 EUR 2023-01-01 – 2023-12-31: -24663000 EUR · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 10000 EUR · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · GenSight Biologics · 2023-12-31 GenSight Biologics (esef:549300NK4AB8OUEX1F54) Free cash flow: -24673000 EUR Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-10T08:41:54Z Snapshot: 09f981f11f49334443a5e46570bc78a4f6976a0e0d97fcf09f8e37a91cb4734d Dimensions: Consolidated View: https://fundies.io/companies/esef/549300NK4AB8OUEX1F54?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -24663000 EUR (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/549300NK4AB8OUEX1F54/2024-12-31/ESEF/FR/0/549300NK4AB8OUEX1F54-2024-12-31-0-EN.zip#30195454 Filing: 549300NK4AB8OUEX1F54-2024-12-31-ESEF-FR-0 Input fundies:CapitalExpenditure: 10000 EUR (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/549300NK4AB8OUEX1F54/2024-12-31/ESEF/FR/0/549300NK4AB8OUEX1F54-2024-12-31-0-EN.zip#30199630 Filing: 549300NK4AB8OUEX1F54-2024-12-31-ESEF-FR-0 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	Unavailable Not reported for this period.	−EUR 12.94 million Exact value Exact value: -12937000 EUR 2024-01-01 – 2024-12-31: -12937000 EUR Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · GenSight Biologics · 2024-12-31 GenSight Biologics (esef:549300NK4AB8OUEX1F54) Operating Cash Flow: -12937000 EUR Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-10T08:41:54Z Snapshot: 09f981f11f49334443a5e46570bc78a4f6976a0e0d97fcf09f8e37a91cb4734d Dimensions: Consolidated View: https://fundies.io/companies/esef/549300NK4AB8OUEX1F54/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=EUR&dimensions= Input fundies:OperatingCashFlow: -12937000 EUR (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/549300NK4AB8OUEX1F54/2024-12-31/ESEF/FR/0/549300NK4AB8OUEX1F54-2024-12-31-0-EN.zip#30194781 Filing: 549300NK4AB8OUEX1F54-2024-12-31-ESEF-FR-0 The citation records this snapshot. The page link may show a newer release later.	EUR 1,000 Exact value Exact value: 1000 EUR 2024-01-01 – 2024-12-31: 1000 EUR Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · GenSight Biologics · 2024-12-31 GenSight Biologics (esef:549300NK4AB8OUEX1F54) Capital Expenditure: 1000 EUR Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-10T08:41:54Z Snapshot: 09f981f11f49334443a5e46570bc78a4f6976a0e0d97fcf09f8e37a91cb4734d Dimensions: Consolidated View: https://fundies.io/companies/esef/549300NK4AB8OUEX1F54/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=EUR&dimensions= Input fundies:CapitalExpenditure: 1000 EUR (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/549300NK4AB8OUEX1F54/2024-12-31/ESEF/FR/0/549300NK4AB8OUEX1F54-2024-12-31-0-EN.zip#30198945 Filing: 549300NK4AB8OUEX1F54-2024-12-31-ESEF-FR-0 The citation records this snapshot. The page link may show a newer release later.	−EUR 12.94 million Calculation and evidence -12937000 − 1000 EUR Exact free cash flow: -12938000 EUR 2024-01-01 – 2024-12-31: -12937000 EUR · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 1000 EUR · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · GenSight Biologics · 2024-12-31 GenSight Biologics (esef:549300NK4AB8OUEX1F54) Free cash flow: -12938000 EUR Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-10T08:41:54Z Snapshot: 09f981f11f49334443a5e46570bc78a4f6976a0e0d97fcf09f8e37a91cb4734d Dimensions: Consolidated View: https://fundies.io/companies/esef/549300NK4AB8OUEX1F54?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -12937000 EUR (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/549300NK4AB8OUEX1F54/2024-12-31/ESEF/FR/0/549300NK4AB8OUEX1F54-2024-12-31-0-EN.zip#30194781 Filing: 549300NK4AB8OUEX1F54-2024-12-31-ESEF-FR-0 Input fundies:CapitalExpenditure: 1000 EUR (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/549300NK4AB8OUEX1F54/2024-12-31/ESEF/FR/0/549300NK4AB8OUEX1F54-2024-12-31-0-EN.zip#30198945 Filing: 549300NK4AB8OUEX1F54-2024-12-31-ESEF-FR-0 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

4 filings · 212 latest values · 212 originally reported values

Dataset published 2026-11-10. Source filing dates and reporting periods are shown separately.

Identifiers: 549300NK4AB8OUEX1F54, esef:549300NK4AB8OUEX1F54

GenSight Biologics

Latest fiscal year

Revenue

Operating margin

Operating cash flow

Free cash flow

Company performance

What changed year over year

Revenue

Operating cash flow

Capital expenditure

Where revenue goes

2024 2024-01-01 – 2024-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation